Summary DNA-testing company 23AndMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests to homes with just a tube of spit. But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening […]

source: https://thefinance.sg/2024/03/08/post-389-how-23andme-went-from-6b-valuation-to-penny-stock-wsj-what-went-wrong/